应用内分支覆膜支架治疗肾旁腹主动脉瘤的单中心经验
本回顾性研究分析23例择期行内分支腔内修复术(iBEVAR)的肾旁腹主动脉瘤患者,采用Artivion® E-xtra定制覆膜支架,平均随访15个月。技术成功率96%,随访期间靶血管一期通畅率98.9%、免于再干预率87%,无动脉瘤相关死亡,总生存率78.3%。作者认为该平台治疗肾旁腹主动脉瘤有效且安全,技术成功率高。
要点
- 23例肾旁腹主动脉瘤患者行iBEVAR,技术成功率96%,共置入87个内分支。
- 随访期间靶血管一期通畅率98.9%,免于再干预率87%,无动脉瘤相关死亡。
- 2例(8.3%)发生术中靶血管夹层,2例(8.3%)术后30天内死亡。
核心结论
- 作者认为,本研究证实了既往结论,即基于Artivion® E-xtra设计平台行iBEVAR治疗肾旁腹主动脉瘤有效且安全,技术成功率高。
研究设计与样本
- 单中心回顾性研究,分析前瞻性收集的行择期内分支腔内修复术(iBEVAR)并使用Artivion® E-xtra定制覆膜支架的患者数据,共23例(19例男性,年龄72.3±7.2岁),观察期56个月,平均随访15个月。
主要发现
- 技术成功率为96%,共置入87个内分支;术中并发症2例(8.3%)均为靶血管夹层,无需额外再干预。
- 术后30天内死亡2例(8.3%),1例死于呼吸衰竭,1例死于缺血性卒中。
- 随访期间3例(13%)需再干预,其中2例修复I型或III型内漏,1例放置初次iBEVAR未成功的髂分支装置。
- 随访期间靶血管一期通畅率为98.9%,免于再干预率为87%,无动脉瘤相关死亡,总生存率为78.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report a single-center result of patients with pararenal aneurysms treated with inner-branched endograft. MATERIALS AND METHODS: This retrospective study analyzed prospectively collected data of patients treated with elective inner-branched endovascular aneurysm repair (iBEVAR) using an Artivion® E-xtra custom-made endograft. Primary endpoints were clinical and technical success after iBEVAR. Secondary endpoints were overall survival, target vessel patency during follow-up, aneurysm-related mortality, and freedom from reintervention. RESULTS: Over a 56-month period, a total of 23 patients (19 men; 72.3±7.2 years) were treated with iBEVAR with a mean follow-up of 15 months. Technical success was achieved in 96% of procedures, incorporating 87 inner branches. Two (8.3%) intraoperative complications (target vessel dissection) were reported, without additional reinterventions needed. Two (8.3%) patients died within 30 days after initial procedure. One due to respiratory failure and the other from an ischemic stroke. During follow-up, 3 patients (13%) required reintervention, either to repair a type I or type III endoleak (n=2) or to place an iliac-branched device, that did not succeed during the initial iBEVAR procedure (n=1). Primary target vessel patency and freedom from reintervention during follow-up was, respectively, 98.9% and 87%. We revealed no aneurysm-related mortality. Overall survival was 78.3%. CONCLUSION: The present study confirms previous findings that iBEVAR on the Artivion® E-xtra design platform is an effective and safe procedure achieving high technical success rate in the treatment of pararenal abdominal aortic aneurysms.Clinical ImpactInner branched stent-graft configuration combines the benefits of FEVAR and outer-branched stent-graft technology. Implementation of inner branches in stent-grafts is gradually becoming more widespread for the treatment of aneurysms. This report supports the safe and high technical success rate of inner branched stent-grafts in treatment of pararenal abdominal aortic aneurysms.
引用
- Yazar O, Huysmans M, Lacquet M, et al. Single-Center Experience With Inner-Branched Endograft for the Treatment of Pararenal Abdominal Aortic Aneurysms. J Endovasc Ther. 2023. PMID: 37846076. doi:10.1177/15266028231204286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。